Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708229 | 0.92 | CA2 (0.35) | CA2PPARGPPARACA1CA9 | |
| SCHEMBL7708221 | 0.87 | PARP1 (0.40) | PARP1 | |
| SCHEMBL7713283 | 0.86 | PARP1 (0.40) | PARP1ITGA4ITGB7 | |
| SCHEMBL7095139 | 0.85 | CA2 (0.41) | CA2CA1CA9CA4CA7 | |
| SCHEMBL7710783 | 0.85 | PPARG (0.39) | PPARGPPARAITGA4ITGB7MMP1 | |
| SCHEMBL7713294 | 0.83 | PARP1 (0.42) | PARP1 | |
| SCHEMBL7708144 | 0.83 | PARP1 (0.42) | PARP1 | |
| SCHEMBL7713338 | 0.83 | PARP1 (0.42) | PPARGPPARAPARP1 | |
| SCHEMBL7713374 | 0.82 | PARP1 (0.50) | PARP1 | |
| SCHEMBL7711371 | 0.82 | PARP1 (0.41) | PPARGPPARAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |